AMCo
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AMCo - overview
Established
2013
Location
London, England, UK
Primary Industry
Pharmaceuticals
About
Based in London, UK, Amdipharm Mercury Company Ltd (AMCo) is a combined business created through the merger of Mercury Pharma and Amdipharm and is a UK-based specialty pharmaceutical company.
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Total Amount Raised
Subscriber access only
AMCo - timeline of key events
AMCo - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 51,477,522 | 56,728,038 | 95,312,659 | 51,870,097 | 51,066,376 | 69,132,880 | 48,766,404 | 64,089,028 | 64,160,000 | - | - | - |
| % Revenue Growth (YoY) | - | 10.2% | 68.0% | (45.6%) | (1.5%) | 35.4% | (29.5%) | 31.4% | 0.1% | - | - | - |
| EBITDA (USD) | 25,433,575 | 28,753,013 | 50,215,630 | 9,722,843 | 4,728,804 | 18,420,652 | 2,009,025 | 58,123 | 995,000 | - | - | - |
| Operating Income (USD) | 24,837,885 | 28,208,292 | 49,620,543 | 8,943,316 | 4,032,636 | 17,657,498 | 1,360,229 | (745,510) | - | - | - | - |
| Operating Margin | 48.2% | 49.7% | 52.1% | 17.2% | 7.9% | 25.5% | 2.8% | (1.2%) | - | - | - | - |
| % EBITDA Margin | 49.4% | 50.7% | 52.7% | 18.7% | 9.3% | 26.6% | 4.1% | 0.1% | 1.6% | - | - | - |
| NET Income (USD) | 19,047,095 | 22,713,979 | 38,391,581 | 6,247,813 | 3,036,221 | 17,264,052 | (13,329,508) | (568,523) | 31,000 | - | - | - |
| % Net Margin | 37.0% | 40.0% | 40.3% | 12.0% | 5.9% | 25.0% | (27.3%) | (0.9%) | 0.0% | - | - | - |
AMCo - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | AMCo | - | ||||||||
| Add-on | Completed | Boucher and Muir | - | ||||||||
| Add-on | Completed | Primegen Limited | - | ||||||||
| Add-on, Trade Sale | Completed | Focus Pharmaceuticals | - | ||||||||
| Merger | Completed | Amdipharm Group, Mercury Pharma Group Limited | - |
Displaying 1 - 5 of 6
AMCo - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.